NEWS
-
2026/05/11 Correctseq
May 11, 2026, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2026/04/24 China Daily
China Daily | Chinese Researchers Debut Breakthrough DNA Repair Tool for Genetic Disorders
A domestically developed gene-editing therapy has successfully treated patients with beta-thalassemia, allowing them to live without the need for lifelong blood transfusions, according to a study published on Wednesday in the journal Nature.
-
2026/04/09 Xinhua Net
In a milestone for genetic medicine, researchers in China have reported the world's first clinical success using a revolutionary "base-editing" technique to treat patients with a severe inherited blood disorder.
-
2026/04/09 Correctseq
In a breakthrough for gene therapy, the international academic journal Nature has published a landmark clinical study detailing the successful use of a novel base-editing drug to treat β-thalassemia.J
-
2025/12/01 Correctseq
CorrectSequence Therapeutics to Participate in the 67th ASH Annual Meeting
December 1, 2025, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aiming to use the innovative gene editing technology to help people with severe diseases,
-
2025/11/07 Correctseq
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
Shanghai, China, November 6, 2025 — CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 targeting APOC3 for chylomicronemia / hypertriglyceridemia has successfully completed dosing and been discharged from the hospital.
-
2025/09/12 Correctseq
ShanghaiTech Scientists Take Major Step Forward in High-precision Mitochondrial DNA Editing
A research team led by Assistant Professor Yang Bei at the School of Life Science and Technology (SLST) and Shanghai Institute for Advanced Immunochemical Studies (SIAIS) and Professor Chen Jia at SLST, ShanghaiTech University, has achieved a significant progress in mitochondrial DNA (mtDNA) editing.
-
2025/08/26 Correctseq
CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced the successful treatment of the first sickle cell disease (SCD) patient using its high-precision base-editing therapy CS-101.